Advanced proton and phosphorous spectroscopy in multiple sclerosis
Research type
Research Study
Full title
Advanced proton and phosphorous spectroscopy in multiple sclerosis: A pilot study to quantify the putative pathology leading to disease progression in vivo
IRAS ID
179098
Contact name
David Paling
Contact email
Sponsor organisation
Sheffield Teaching Hospitals
Duration of Study in the UK
0 years, 8 months, 0 days
Research summary
In this study we plan to use a combination of phosphorous and proton spectroscopy in patients with progressive multiple sclerosis. The aim of this study is to see if alterations in mitochondrial function can be detected using phosphorous spectroscopy in patients with MS as compared to controls, and to see if they are associated with clinical measures of neurological impairment. We additionally plan to assess whether these markers of mitochondrial dysfunction are related with other MRI measures of MS pathology including neuroaxonal loss and dysfunction (NAA) and gliosis (MI).
This study will help to assess whether phosphorous spectroscopy is sensitive to clinically relevant MS pathology, and would serve to inform design of larger longitudinal studies. In the longer term finding sensitive and responsive MRI biomarkers of the pathology underlying progressive multiple sclerosis could help in the design and testing of disease modifying drugs for this stage of the disease.REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
15/YH/0319
Date of REC Opinion
16 Sep 2015
REC opinion
Further Information Favourable Opinion